A little-known stock started to make a huge name for itself in 2024. That stock is GeneDX (NASDAQ: WGS). Through the course of 2024, this healthcare company increased its market capitalization from under $70 million to over $2 billion. That is a return of just under 2700%. What is just as interesting is that despite the stock’s massive run-up, multiple Wall Street analysts still believe there is upside.
Among four price targets tracked by MarketBeat since Oct. 2024, their average sits at $89.50 per share. Compared to the company’s Jan. 30 closing price of just under $78, that implies nearly 15% upside. The most recently updated target by analysts at TD Cowen is particularly bullish, sitting at $118. The research firm’s target, released on Jan. 7, indicates shares could still rise by 51%.
